Macupatide (LY-3532226) is under development for the treatment of type 2 diabetes, obesity and type 1 diabetes mellitus. It is administered through subcutaneous route. It is a long acting new ...
Here are some clinical trials that could send Big Pharma shares soaring, or crashing, in 2025. Eli Lilly. The world’s biggest ...
In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other healthcare stocks Jim Cramer has made bold predictions about. Healthcare has been ...
LY-4101174 is under clinical development by Eli Lilly and Co and currently in Phase I for Cervical Cancer. According to GlobalData, Phase I drugs for Cervical Cancer have an 80% phase transition ...
Novo Nordisk’s Ozempic and Wegovy continue to outpace Eli Lilly’s Mounjaro and Zepbound, even though the latter are ...
Eli Lilly and Novo Nordisk are the two biggest names in the pharmaceutical sector, but I see one as the clear-cut winner for ...
The story of Eli Lilly and Novo Nordisk’s GLP-1 dominance is likely to play out again in 2025 as the metabolic medicine ...
Eli Lilly is joining in a lawsuit filed by the Outsourcing Facilities against the FDA, aiming to reverse the FDA's October 2024 determination that the shortage has been resolved, which would allow ...
Eli Lilly's biggest catalyst at the moment comes from its hit weight loss medications, Mounjaro and Zepbound. Lilly is ...
Insider Monkey on MSN4d
Jim Cramer’s Take on Eli Lilly and Company (LLY): Bold Predictions for the FutureIn this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other ...
Eli Lilly's Zepbound drug holds potential to dominate the global obesity market due to its superior efficacy and strategic ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback